New drug can help stop certain breast cancer tumours early, trial shows
A trial called Serena-6 shows that camizestrant stops cancer cells from using hormones to grow, which helps patients stay well longer and delays the need for chemotherapy.
It is the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients, scientists say.
The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases.
Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with just standard therapies.
Doctors used a simple blood test to spot changes in the cancer's DNA that show whether current treatments might soon stop working.
When they found these signs, some patients were given camizestrant, while others stayed on their usual treatment.
Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others.
The drug was safe for most patients but 1% stopped taking it because of side effects.
More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London.
Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'.
Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.'
About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said.
The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday.
Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment.
'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow.
'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions.
'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
21 hours ago
- The Guardian
If AstraZeneca goes to the US it will be a major blow for London and Labour
Three years ago Pascal Soriot received the ultimate accolade for turning around AstraZeneca – a knighthood for services to UK life sciences and leadership in the global response to the Covid pandemic. Soriot, who fended off a takeover from the US predator Pfizer in 2014, has grown AstraZeneca into Britain's most valuable company, thanks to an astute eye for promising medicines and developing one of the first Covid vaccines. Now the 66-year-old trained equine vet is looking at his own US adventure. He has reportedly discussed moving AstraZeneca's stock market listing, and perhaps even its corporate base, to the US. The company declined to comment on the bombshell report, but it sent shockwaves through Britain's scientific community. It also threatens to topple a key pillar of the government's fledgling industrial strategy and deprive the London market of its biggest star. The FTSE 100 company's share price rose by 2.8% on Tuesday, with most of the gains coming after the news, but dipped by 0.2% on Wednesday, giving the company a value of nearly £161bn, ahead of Shell at almost £155bn. Soriot, the UK's best-paid chief executive of a listed company, has made no secret of his growing frustration with the UK authorities in recent months. AstraZeneca's breast cancer drug Enhertu has not been approved for use on the NHS in England and Wales even though the company offered a low price, he claimed. The medication is available in Scotland and most other European countries. Another flashpoint came in late January, when the pharma group ditched its planned £450m investment to turn its factory in Speke near Liverpool into a major vaccine hub after failing to to agree with ministers on the size of state support. But Soriot's – and other pharma bosses' – biggest gripes are with the wider regulatory and commercial environment in the UK and the rest of Europe. They have called for more healthcare spending and a single list price for medicines across Europe, similar to the US, plus discounts for specific countries linked to their GDP and wealth. The UK's spending on new medicines does not compare well internationally, as Soriot has noted – amounting to 7% of healthcare costs versus 10 to 11% in many other European countries and 13 to 15% in the US. It also takes much longer to run a clinical trial. 'Companies will go where they feel welcome because access to our medicines is good, innovation is rewarded. And of course, tax policies also play a role in all those decisions,' he has said. Otherwise, well-paid advanced manufacturing and research jobs could move to the US in the long run, he said in April. Soriot, who grew up in the Parisian banlieues, has reiterated the company's commitment to the UK. It has poured more than £1bn into a new global headquarters and research centre in Cambridge in recent years. This was dwarfed, however, by its recent $3.5bn investment in US research and manufacturing, including turning its Kendall Square labs in Cambridge, Massachusetts, into a state-of-the art research hub – a wise move before Donald Trump's threatened tariffs on the pharmaceutical sector. The suggestion that AstraZeneca could up sticks comes at difficult time for Keir Starmer's government, which is on the back foot on many fronts. Just this week, it had to postpone publication of its long-awaited life sciences strategy because negotiations between ministers and the pharmaceutical industry about drug pricing have stalled. The 10-year plan will be coming shortly, according to the Department for Science, Innovation andTechnology. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion Whether Soriot is seriously considering a move stateside, and manages to win over the board and shareholders, is unclear. But 'the mere talk of the biggest listed company leaving London will get ministers sitting up and listening,' said the Hargreaves Lansdown analyst Susannah Streeter. The chancellor's Mansion House speech later this month, when Rachel Reeves is expected to outline ways to revitalise London as a financial hub, will be closely watched for evidence of concrete plans to increase liquidity and make it easier for firms to list. 'At a time when the government and regulators are laying out plans to make the City more attractive, if this move being mulled by AstraZeneca were to become a reality, it would be another big setback for London,' said Streeter. 'The more company boards are reported to be discussing such a strategy, the more likely it will be that other firms will embark on similar discussions to assess whether moving main listings could help boost valuations.' It would be the biggest blow yet to the London Stock Exchange, which has lost a string of big names in recent months. Streeter said losing such a big player on the London market would make it even harder to lure more firms to list on the LSE. For Labour's creaking government, it is a headache they could do without.
The Independent
a day ago
- The Independent
What AstraZeneca could cost London's stock market if it moves to US
AstraZeneca 's CEO, Pascal Soriot, has reportedly held private discussions about moving the pharmaceutical firm's stock market listing from London to the US. The potential move is primarily driven by the CEO's long-standing frustrations with UK regulations, including restrictions on new medicines and pricing structures. Such a shift would represent a significant blow to the London Stock Exchange, as AstraZeneca is currently its largest listed company with a market capitalisation exceeding £161bn. The US is AstraZeneca's largest revenue source, contributing $21.8bn (£15.3bn) of its $54bn (£39bn) total revenue in 2024, highlighting the market's importance to its growth strategy. The company previously abandoned plans for a £450m vaccine hub near Liverpool, citing 'timing' and a funding gap, amid ongoing discussions with the UK government regarding pharmaceutical industry support.
The Independent
a day ago
- The Independent
Fears over £160bn blow to London's stock market as AstraZeneca considers listing move to US
The boss of AstraZeneca, the biggest company on the London Stock Exchange, has discussed shifting the pharmaceutical firm's stock market listing to the US. Such a move would be the biggest hit to the stock market yet, following some huge departures such as £10bn financials firm Wise and £40bn mining business Glencore, among others. The pharmaceutical firm however is far bigger by market capitalisation, currently worth just over £161bn – more than BP, National Grid and Lloyds Bank combined. Pascal Soriot is the chief executive who has held private conversations over moving the listing, first reported the Times, citing frustrations with restrictions around new medicines and pricing structures. The Independent understands the company acknowledges the CEO's concerns as being longstanding, especially regarding new products, while conversations are ongoing with the UK government over support for the wider pharmaceutical industry, particularly when it comes to supporting the commercial environment to become a global superpower in the sector. While the stock market listing would naturally be a huge blow for the UK markets, Mr Soriot could seek to re-domicile the company in the US too. That would bring political pressure too amid a potential huge blow for the government as they both chase economic growth and also get ready to back life sciences as one of the pillars mentioned in the recent industrial strategy. Earlier this year, AstraZeneca ditched plans for a £450m vaccine hub near Liverpool, with 'timing' cited as a reason at the time, while a £12m funding gap was also apparent. While the Conservatives had initially agreed the deal including a £90m pledge, Labour found no record of it after taking power and eventually only committed to £78m. 'Reports that AstraZeneca wants to move its stock listing to the US looks to be driven by business needs rather than chasing a higher valuation,' commented Dan Coatsworth, investment analyst at AJ Bell. 'America is important to its growth strategy and it could become an even bigger cog in the wheel. 'The CEO seems frustrated at the lack of financial support to open new laboratories and manufacturing facilities in Europe and might see a full US stock listing as a stepping stone to receiving better treatment Stateside. 'It won't be an easy move to pull off as unlike many other UK market 'defectors' with a dominant US shareholder base like CRH and Flutter, AstraZeneca has a more geographically diverse pool of investors.' Meanwhile, one key focus of President Trump's tariff plans have been to encourage - or demand - more pharmaceutical companies ply their trade in the US. The EU are trying to arrange in a trade deal for pharmaceuticals to be one of the industries which get a lower than 10 per cent base tariff for exports. A total of 40.4 per cent of AstraZeneca's total $54bn (£39bn) revenue for 2024 came from the US alone: $21.8bn (£159bn), compared to $11.7bn from Europe and $12.6bn from Asia, Africa and Australasia combined. AstraZeneca does already have American depositary receipts trading in the US, which allows investors to locally trade in their shares. At the close of Monday's market, their share price on the LSE had risen more than 2 per cent to above £104, before falling back 0.5 per cent lower in Tuesday morning trading. When contacted, the company did not directly comment on any listing speculation. Board approval would be required to move the shares overseas. Mr Soriot earned £16.85m in 2023 as the highest-paid CEO among any FTSE 100 firm.
